US firm acquires Waterford drug facility for €55m

40 EirGen employees will transfer to Horizon with 50 extra staff to be recruited

EirGen Pharma develops and supplies high potency specialty care medicines.

Waterford pharmaceutical firm EirGen is to sell a drug product manufacturing facility to US firm Horizon Therapeutics in a deal worth almost €55m.

As part of the transaction, approximately 40 EirGen employees at the plant will transfer to Horizon following the close of the transaction. Horizon intends to recruit 50 additional staff for the site in 2021 and 2022.